Asset
INSULIN ASPART
Revenue
No revenue reported in loaded filings.
Clinical trials (109)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01713530 | phase3 | completed | 2013-02-21 | 2014-01-09 | Novo Nordisk A/S | A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin |
| NCT02906917 | phase3 | completed | 2016-09-20 | 2017-08-31 | Novo Nordisk A/S | A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification |
| NCT01125553 | phase1 | completed | 2010-05-01 | 2010-08-01 | Novo Nordisk A/S | A Comparison Between Two Formulations of NN5401 in Healthy Subjects |
| NCT01059812 | phase3 | completed | 2010-02-01 | 2010-12-23 | Novo Nordisk A/S | A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| NCT01814137 | phase3 | completed | 2013-03-01 | 2014-03-01 | Novo Nordisk A/S | A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily |
FDA applications (3)
| Application | Type | Applicant |
|---|---|---|
| BLA 020986 | BLA | Novo Nordisk Inc. |
| BLA 203313 | BLA | Novo Nordisk Inc. |
| BLA 208751 | BLA | Novo Nordisk Inc. |
Marketed products (10)
- FIASP
- FIASP FLEXTOUCH
- FIASP PENFILL
- Fiasp
- NOVOLOG
- NOVOLOG FLEXPEN
- NOVOLOG FLEXTOUCH
- NOVOLOG INNOLET
- NOVOLOG PENFILL
- RYZODEG 70/30